Inefficiencies in COPD Clinical Trials
Per Study Cost
Source: HHS

According to research by the U.S. Department of Health and Human Services, the therapeutic area with the highest clinical research cost is the respiratory system (source).
Underlying cost drivers in these trials include:
- Complex disease process
- Imprecise conventional endpoints
- Operational challenges
These factors drive large subject cohorts, study site complexities, and data quality issues that extend trial timelines and costs.
Data Quality
Biomarker Reliability
Reliability in quantitative CT (QCT) is determined by the consistency (or repeatability) of a measure. QCT measurement consistency (test/re-test) for 38 of VIDA’s digital imaging biomarkers was recently published in the American Journal of Respiratory and Critical Care Medicine (source). This important study showed high repeatability and reliability for QCT measures and revealed the importance of high-quality data and performing quality control (QC), which improved repeatability and reliability.

Modern Trial Imaging Management
Not all quantitative imaging data is equal.
To optimize data quality and streamline operational ease, VIDA provides a full range of trial imaging management services, built upon 20+ years of experience. These services are enabled by the VIDA Intelligence Platform, a modern AI-powered trial imaging system.
Since introduction of the innovative platform in early 2022:

*Among trials where imaging metrics are the primary endpoint.
VIDA is proud to be the lead Quantitative CT (QCT) imaging provider for SPIROMICS, a large multi-site COPD study for the purpose of identifying subpopulations and intermediate outcome measures.
More Resources
If you are interested to learn more about Quantitative Imaging Biomarkers for COPD, or our trial imaging services in general, we’d love to speak with you.
If addition, please enjoy the following programs and resources related to Clinical Trial Imaging for COPD:
COPD Studies Utilizing VIDA’s Precision Quantitative Imaging Solution






